GlassScriptPhysician profile
Courtney Kaiser
NPI 1184142226
$3,745.82
in general payments reported to CMS, 2019-2025
31 companies · $779 in 2025
The $779 reported for 2025 was more than what 87% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $736 · 2022: $454 · 2023: $477 · 2024: $1,300 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $859.09 | 2021-2025 | |
| Ucb, INC. | $650.83 | 2021-2025 | Briviact, Fintepla, Zilbrysq |
| Abbvie INC. | $403.59 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $166.69 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $163.84 | 2022-2024 | Ultomiris, Soliris |
| Lilly USA, LLC | $156.64 | 2021-2025 | Kisunla, Amyvid, Reyvow |
| Ge Healthcare | $141.27 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $120.45 | 2021-2024 | Xeomin, Inbrija |
| Neurelis, INC. | $114.85 | 2021-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $108.69 | 2021-2024 | Rytary |
| Lundbeck LLC | $102.01 | 2021-2024 | Vyepti |
| Neurocrine Biosciences, INC. | $87.93 | 2024-2025 | Ingrezza |
| Kyowa Kirin, INC. | $78.75 | 2023-2024 | Nourianz |
| Amgen INC. | $75.55 | 2021-2022 | |
| Eisai INC. | $73.31 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $56.96 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $44.02 | 2024 | Andexxa |
| Genzyme Corporation | $37.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.72 | 2022 | |
| Mallinckrodt Hospital Products INC. | $31.85 | 2021 | |
| Novocure INC. | $28.65 | 2025 | Optune Gio |
| Alnylam Pharmaceuticals INC. | $26.75 | 2024 | Onpattro |
| Integra Lifesciences Corporation | $26.38 | 2024 | Biodfactor, Medihoney, Biodoptix |
| Biohaven Pharmaceuticals, INC. | $25.07 | 2021 | |
| Argenx US, INC. | $22.09 | 2025 | Vyvgart Hytrulo |
| Azurity Pharmaceuticals, INC. | $21.57 | 2024 | Horizant |
| Otsuka America Pharmaceutical, INC. | $20.86 | 2025 | Rexulti |
| Banner Life Sciences, LLC | $19.73 | 2022 | |
| Nevro Corp. | $16.49 | 2021 | |
| Cala Health, INC. | $15.62 | 2025 | Cala Kiq |
| Merz North America, INC. | $14.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.